Approval of COVID-19 test in the UK under CTDA legislation

Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXTGROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics,announces that, further to the announcement on 2 November 2021, the Company’sgenesig® COVID-19 Real-Time PCR test has been approved in the UK under the UK HealthSecurity Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment)Regulations 2021

Visit Page

Validation of COVID-19 tests in the UK under CTDA legislation

Paris, France and Camberley, UK – 2 November 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the availability of its COVID-19 tests in the UK following implementation of the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”). http://novacyt.com/wp-content/uploads/2021/11/Novacyt-Validation-of-COVID-19-tests-in-the-UK-under-CTDA-FINAL-ENG.pdf

Visit Page

R&D update

Including launch of two new tests to differentiate between COVID-19 and common winter viruses, and between COVID-19 variants Paris, France and Camberley, UK – 30 September 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an R&D update. http://novacyt.com/wp-content/uploads/2021/09/Novacyt-RD-update.pdf

Visit Page